At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 71 enrolled
Drug / intervention
AZD2423 +1 moredrug
Likely dose
AZD2423 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase IIa Study to Investigate the Effects of 100mg AZD2423 as an Oral Tablet in Subjects With Mild COPD Following Segmental Endobronchial LPS Instillation
In Brief
A Phase 2 clinical trial evaluating AZD2423 and AZD2423 Placebo for Chronic Obstructive Pulmonary Disease and Lung Disease. Completed, enrolled 71 participants across 1 site.
Detailed Summary
The purpose of the study is to find out if AZD2423 can reduce inflammation in the lungs of patients with mild COPD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2010
Enrollment StartOct 2010
Primary CompletionJul 2011
TodayJul 2026
First PostedJun 30, 2010
Enrollment StartOct 1, 2010
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 16.0 years ago
Interventions
AZD2423drug
100mg Oral dose od
AZD2423 Placebodrug
Oral dose od